Creatine, the Gym Supplement, May Supercharge the Immune Cells That Fight Cancer, Study Finds

Creatine, the supplement millions of gymgoers take to build muscle, may have a far more consequential job: sharpening the immune system's ability to hunt down cancer. That is the finding of a new study from UCLA researchers, who report that the compound energizes a class of immune cells that sits at the very heart of the body's defense against tumors.

The study, published in the journal iScience, focused on dendritic cells — the immune system's scouts. These cells detect the telltale molecular flags of a tumor and then activate "killer" T cells, the assassins that destroy cancerous tissue. Without well-functioning dendritic cells, the killer T cells never get the order to attack. The UCLA team found that creatine supercharges those scouts.

In mouse models of melanoma, an aggressive skin cancer, creatine supplementation significantly slowed tumor growth and increased both the number and the activation of dendritic cells. The effect was mirrored in experiments on human cells, suggesting the mechanism is not a quirk of mouse biology but something that could translate to patients. Creatine, it turns out, helps power the energy-hungry process by which dendritic cells rev up and marshal the rest of the immune response.

The potential clinical payoff is substantial. Many of today's most celebrated cancer immunotherapies are designed to unleash killer T cells, but they work well in only about 20% to 40% of patients — a frustrating ceiling that has puzzled oncologists for years. The UCLA researchers argue that the missing piece may be upstream: if the dendritic cells directing those T cells are underpowered, even the best T-cell therapy will stall. Boosting dendritic-cell function with something as cheap and widely available as creatine could, in theory, widen the circle of patients who benefit.

The researchers were careful to temper expectations. The results, while striking, have not yet been tested in human cancer patients, and a supplement that helps mice with melanoma is a long way from an approved therapy. Dosing, safety in combination with existing drugs, and whether the effect holds across different cancer types all remain open questions that clinical trials will need to answer.

Still, the appeal of the idea is hard to ignore. Creatine is one of the most-studied and least-expensive supplements on the market, with a long safety record in healthy adults. If a compound already sitting on drugstore shelves can make cutting-edge immunotherapy work for more people, it would be a rare piece of good news in cancer care — one that costs pennies rather than the tens of thousands of dollars that many modern treatments command. For now, the message from UCLA is a promising lead, not a prescription: the science is early, but the direction is intriguing.